Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer
10.3971/j.issn.1000-8578.2022.22.0038
- VernacularTitle:CD44v6和EGFR表达对Ⅱ~Ⅲ期宫颈癌新辅助化疗敏感度的预测价值
- Author:
Wanli MAO
1
;
Li RAN
;
Jiehui LI
;
Fenghu LI
;
Jianying CHANG
;
Junyu MU
;
Fan MEI
;
Lili HU
;
Yanjun DU
;
Xue TIAN
;
Yao QIN
;
Shuishui YIN
Author Information
1. Department of Gynecological Oncology, Guizhou Medical University Cancer Hospital, Guiyang 550004, China
- Publication Type:Research Article
- Keywords:
Cervical cancer;
Neoadjuvant chemotherapy;
CD44v6;
EGFR
- From:
Cancer Research on Prevention and Treatment
2022;49(9):937-943
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the predictive value of the expression of CD44v6 and EGFR on the efficacy of neoadjuvant chemotherapy (NACT) in stageⅡ-Ⅲ cervical cancer. Methods A total of 53 patients with stageⅡ-Ⅲ cervical cancer diagnosed by pathology were selected. All patients received two cycles of paclitaxel+platinum NACT. The pathological tissue samples of cervical tumors before NACT treatment were collected. The expression of CD44v6 and EGFR were detected by the immunohistochemical SP method, and we analyzed their predictive value of NACT in stageⅡ-Ⅲ cervical cancer. Results Among the 53 patients, 38 were in the NACT effective group (CR+PR), and 15 were in the NACT ineffective group (SD+PD). The expression of CD44v6 in the ineffective group was significantly higher than that in the effective group (P < 0.05). The expression of CD44v6 was significantly different in patients with CR, PR, and SD (P < 0.05). The AUC of CD44v6 to NACT effect on stage Ⅱ-Ⅲ cervical cancer was 0.74 (P < 0.05). The patients in the high expression group of CD44v6 had worse efficacy in NACT than those in the low expression group of CD44v6 (P < 0.05). Pearson test showed that CD44v6 and EGFR expression were correlated (R=0.34, P < 0.05). Conclusion High expression of CD44v6 may reduce the efficacy of NACT in stageⅡ-Ⅲ cervical cancer, suggesting that the expression of CD44v6 has a certain predictive value and clinical significance in the efficacy of paclitaxel+platinum NACT on cervical cancer. Moreover, CD44v6 is positively correlated with EGFR expression.
